scholarly journals 561 Metastasectomy for Stage IV Melanoma in the Effective Systemic Treatment Era

2021 ◽  
Vol 108 (Supplement_6) ◽  
Author(s):  
M J Corbetta Machado ◽  
R Gourlay ◽  
A Majid ◽  
A Van der Westhuizen
Keyword(s):  
Survival Curve ◽  
Survival Rates ◽  
Stage Iv ◽  
Braf Inhibitors ◽  
Inclusion Criteria ◽  
Mater Hospital ◽  
Disease Characteristics ◽  
Kaplan Meier ◽  
Melanoma Patients ◽  
Stage Iv Melanoma

Abstract Aim Historically, a diagnosis of Stage IV melanoma was a dire one, with low survival rates and ineffective treatment. The only beneficial treatment option was metastasectomy in very selected cases. The recent introduction of the effective systemic therapy agents (EST) (immunotherapy and BRAF inhibitors) dramatically changed this. This research’s aim is to determine if EST + Metastectomy significantly improves OS. And if so, should be considered as the main therapeutic approach to stage IV melanoma patients. Method Single-centre retrospective cohort study from the Melanoma Unit at Calvary Mater Hospital in Australia was conducted, approved by the ethics committee. Inclusion criteria was Stage IV Melanoma patients who received EST from 2009-2019. OS of those who received EST alone are compared to EST + Metastasectomy. The 2 groups were compared retrospectively based on their disease characteristics, using probability score weighting analysis and survival curve. Results This is a preliminary analysis for the first 200 patients, data collection is ongoing. Mean OS is 2 years. Several combinations of immunotherapy treatments were identified. Of the 200 patients, 35% underwent metastasectomy. Mean survival for those who had surgery is 3 years, as oppose to 2 years for those who had EST alone. OS in the Metastasectomy group was higher than those who had EST alone, of 47.1% and 42.3% respectively. The Kaplan Meier curve also shows increase survival in the metastasectomy group, up to year 6 post diagnosis. Conclusions Metastasectomy for stage iv melanoma in the EST era appears to offer a survival benefit in selected patients

scholarly journals Long-term Survival of Stage IV Melanoma Patients Treated with BOLD Combination Chemotherapy and Intermediate-dose Subcutaneous Interferon-alpha

2018 ◽  
Vol 38 (11) ◽  
pp. 6393-6397 ◽  
Author(s):  
KALLE MATTILA ◽  
PIRITA RAANTA ◽  
VALTTERI LAHTELA ◽  
SEPPO PYRHÖNEN ◽  
ILKKA KOSKIVUO ◽  
...  
Keyword(s):  
Interferon Alpha ◽  
Combination Chemotherapy ◽  
Stage Iv ◽  
Term Survival ◽  
Long Term Survival ◽  
Melanoma Patients ◽  
Stage Iv Melanoma ◽  
Intermediate Dose

Circulating Tumor Cells in Stage IV Melanoma Patients

2018 ◽  
Vol 227 (1) ◽  
pp. 116-124 ◽  
Author(s):  
Carolyn S. Hall ◽  
Merrick Ross ◽  
Jessica B. Bowman Bauldry ◽  
Joshua Upshaw ◽  
Mandar G. Karhade ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Stage Iv ◽  
Melanoma Patients ◽  
Stage Iv Melanoma

Abstract 2847: Quantitative assessment of circulating BRAF DNA in stage IV melanoma patients undergoing BRAF inhibitor treatment

2014 ◽  
Author(s):  
David Polsky ◽  
Jyothi Sakuntala Tadepalli ◽  
Gregory Chang ◽  
Nathaniel Fleming ◽  
Yongzhao Shao ◽  
...  
Keyword(s):  
Quantitative Assessment ◽  
Braf Inhibitor ◽  
Stage Iv ◽  
Melanoma Patients ◽  
Inhibitor Treatment ◽  
Stage Iv Melanoma

scholarly journals Combining chemotherapy and autologous peptide‐pulsed dendritic cells provides survival benefit in stage IV melanoma patients

2020 ◽  
Vol 18 (11) ◽  
pp. 1270-1277
Author(s):  
Klaus Eisendle ◽  
Georg Weinlich ◽  
Susanne Ebner ◽  
Markus Forstner ◽  
Daniela Reider ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
Survival Benefit ◽  
Stage Iv ◽  
Melanoma Patients ◽  
Stage Iv Melanoma

Systematic Review: Surgery for Patients with Metastatic Melanoma during Active Treatment with Ipilimumab

2014 ◽  
Vol 80 (8) ◽  
pp. 805-810 ◽  
Author(s):  
Justin J. Baker ◽  
Karyn B. Stitzenberg ◽  
Frances A. Collichio ◽  
Michael O. Meyers ◽  
David W. Ollila
Keyword(s):  
Systematic Review ◽  
Foreign Language ◽  
Cutaneous Melanoma ◽  
Surgical Intervention ◽  
Stage Iv ◽  
Limited Data ◽  
Inclusion Criteria ◽  
Search Terms ◽  
Institutional Experience ◽  
Stage Iv Melanoma

Studies of ipilimumab have shown improved overall survival in patients with metastatic cutaneous melanoma. As a result, use of ipilimumab in patients with Stage IV melanoma is rapidly increasing. Patients with Stage IV melanoma often require urgent operations for complications from metastases, but little is known about the safety of surgical intervention for patients receiving ipilimumab. We performed a systematic review of the literature using PubMed. Our search terms were melanoma and ipilimumab. We excluded foreign language articles, review articles, and those not addressing cutaneous melanoma. We identified 194 publications matching the search criteria. Only six of those met the inclusion criteria. In these six publications, seven patients who had undergone surgical intervention during treatment with ipilimumab were described. There were no documented surgical complications. We reviewed our institutional experience and identified an additional three patients. No postoperative complications could be attributed directly to ipilimumab. There are limited data on the safety of surgical intervention during treatment with ipilimumab. Preliminary reports suggest there is no reason to withhold or delay surgery for patients receiving ipilimumab therapy.

Monocyte-derived IL-10 Expression Predicts Prognosis of Stage IV Melanoma Patients

2007 ◽  
Vol 30 (8) ◽  
pp. 831-838 ◽  
Author(s):  
Hitoe Torisu-Itakura ◽  
Jonathan H. Lee ◽  
Young Huynh ◽  
Xing Ye ◽  
Richard Essner ◽  
...  
Keyword(s):  
Stage Iv ◽  
Melanoma Patients ◽  
Stage Iv Melanoma

Weekly paclitaxel and carboplatin may be an option for salvage chemotherapy in stage IV melanoma patients

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 7572-7572
Author(s):  
S. G. Holtan ◽  
R. D. Rao ◽  
E. Creagan ◽  
J. Kaur ◽  
H. Pitot ◽  
...  
Keyword(s):  
Stage Iv ◽  
Salvage Chemotherapy ◽  
Weekly Paclitaxel ◽  
Melanoma Patients ◽  
Stage Iv Melanoma

Predictors for survival in hepatocellular carcinoma.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e14640-e14640
Author(s):  
Glen I. Misek ◽  
Venkata K Jayanti
Keyword(s):  
Hepatitis C ◽  
Hepatitis B ◽  
Treatment Initiation ◽  
Early Stage ◽  
Survival Rates ◽  
Stage Iv ◽  
First Line ◽  
Kaplan Meier ◽  
History Of ◽  
One Year

e14640 Background: The global incidence of HCC is over 700,000 patients making it the sixth leading cancer and the prognosis is poor with a 5 year survival of 11%. It is important to understand if there are differences in survival based on the presence of Hepatitis B or C or alcohol cirrhosis, ethnicity and/or treatments employed in various stages of the disease. Methods: A robust global retrospective study of HCC patients was conducted with nearly 4,000 patient records from US, Germany, France, Spain, Italy, China and South Korea in 2011. Of these nearly 800 included deceased patients. These records were analyzed to study if any known factors such as ethnicity, presence of Hepatitis B, Hepatitis C or alcohol cirrhosis and/or treatments used at diagnosis could serve as predictors for survival. Kaplan-Meier curves were plotted to understand the differences in survival based on ethnicity, Child-Pugh status and treatments employed at various stages. Results: One year survival is lower in China/ Korea compared to US and EU, however, five year survival rates are comparable across regions. Associated hepatitis or cirrhosis does not convey any differences in one year survival whether patients received sorafenib as first line treatment or not. Statistically significant higher one year survival rates are observed for HCC patients in Europe and USA receiving transarterial chemoembolization (TACE) compared with patients receiving sorafenib first line. However, in China and Korea there is no such difference. Across all three regions: USA, EU and Asia there is no difference in survival in stage IV patients receiving sorafenib or no sorafenib. No significant differences in one year survival are seen in USA, EU and Asia for patients with Hepatitis C or B or cirrhosis compared to those with no history of liver disease. The Child-Pugh C patients had lower survival compared to Child-Pugh A or B patients. Conclusions: Early diagnosis of HCC, early intervention and treatment appear to show survival benefits as opposed to drug treatment with sorafenib initiated in the later stages of the disease. Efforts should increase for screening, early detection and treatment initiation at early stage to improve outcomes in HCC patients.

Preoperative peripheral blood lymphocyte/monocyte ratio and survival in patients with resected stage IV melanoma.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 8600-8600
Author(s):  
Nicole M. Rochet ◽  
Luis F. Porrata ◽  
Lisa A. Kottschade ◽  
Travis Edward Grotz ◽  
Svetomir Markovic
Keyword(s):  
Prognostic Factor ◽  
Proportional Hazards ◽  
Complete Blood Count ◽  
Stage Iv ◽  
Independent Prognostic Factor ◽  
Monocyte Count ◽  
Continuous Variables ◽  
Melanoma Patients ◽  
Chi Square Analysis ◽  
Stage Iv Melanoma

8600 Background: The prognosis of stage IV melanoma patients remains poor. Published results have suggested that components of the complete blood count have significant prognostic value in several malignancies. Among the most studied were the absolute lymphocyte count (ALC), and absolute monocyte count (AMC) on clinical outcomes of patients with lymphoid malignancies. Thus, we sought to investigate if the pre-operative ALC (ALC-PO), AMC (AMC-PO) and ALC/AMC ratio (ALC/AMC-PO) affects the risk of disease recurrence and survival after complete surgical resection of metastatic melanoma. Methods: We studied 66 stage IV, resected melanoma patients followed at Mayo Clinic from 2000 to 2010. Log rank chi-square analysis was used to determine the best cut-off values for each pre-operative variable, while proportional hazards models were used to compared survival. Results: The median follow-up of the cohort was 24 months (range: 2.3 – 117 months). ALC-PO, AMC-PO and ALC/AMC-PO, as continuous variables, were all identified as prognostic factors for both relapse-free survival (RFS) and overall survival (OS). The best cut-off values for ALC-PO, AMC-PO and ALC/AMC-PO were 1.9; 0.62; and 2.05, respectively. Using Kaplan-Meier analysis, patients with an ALC-PO ≥ 1.9 x 109/L experienced superior OS and RFS compared with ALC-PO < 1.9 x 109/L patients [median OS of 58 months vs. 34 months, p < 0.04; median RFS of 14 months vs. 5 months, p < 0.009]. Conversely, a low AMC-PO (<0.62 x 109/L) was associated with better OS and RFS compared with higher AMC-PO (≥ 0.62 x 109/L): [median OS of 47 months vs. 14 months, p < 0.007; median RFS of 9 months vs. 5 months, p < 0.02]. When the ALC-PO and AMC-PO were combined as an ALC/AMC ratio, the group with an ALC/AMC-PO ≥ 2.05 experienced a superior OS and RFS compared to patients with ALC/AMC-PO < 2.05: [median OS of 49 months vs. 12 months, p < 0.0001; median RFS of 10 months vs. 4 months, p < 0.0001]. Multivariate analysis showed ALC/AMC-PO to be an independent prognostic factor for RFS and OS (HR = 0.32, p < 0.003; HR = 0.23, p < 0.002). Conclusions: Our study showed, that ALC/AMC-PO ratio is an independent prognostic factor for RFS and OS in patients undergoing resection of metastatic (stage IV) melanoma.

Sign in / Sign up

Export Citation Format

Share Document